An evaluation is in process.
A follow-up report will be submitted when the evaluation is complete.
This report is being filed on an international product, list number 06c30 that has a similar product distributed in the us, list number 6l21.
Patient identifier: sid (b)(6).
|
The customer observed a false nonreactive architect (b)(6) for a patient.
On (b)(6) 2020 sid (b)(6) generated an initial result = 0.
84.
S/co (grayzone); repeat result = 0.
77 s/co (nonreactive); on (b)(6) 2020 repeat result = 0.
93 s/co (grayzone).
The sample was sent (b)(6) hospital for confirmation and generated a reactive result on an architect i2000sr analyzer.
On (b)(6) 2020 the customer provided additional patient information: on (b)(6) 2020 sid (b)(6) = initial result = 0.
81 s/co (grayzone), repeat results = 0.
77 s/co (nonreactive), 0.
93 s/co (grayzone), (b)(6) hospital for confirmation = reactive.
|